Clinical Physiology Associates — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$8,712	1
2022	Research	$4,754	7
2021	Research	$11,090	8
2020	Research	$9,511	7
2019	Research	$199,794	46

Breakdown

Who paid Research payments · program years 2019–2023

AMAG Pharmaceuticals, Inc. $65,616 8 payments
Pfizer Inc. $58,333 9 payments
Mitsubishi Tanabe Pharma Development America, Inc. $43,490 3 payments
AbbVie, Inc. $26,201 26 payments
American Regent $19,166 9 payments
Myovant Sciences Inc. $12,343 13 payments
Sumitomo Pharma America, Inc. $8,712 1 payment

Studies the money was for Research payments · program years 2019–2023

Prasterone DHEA for the Treatment of Hypoactive Sexual Desire Disorder HSDD - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone $65,616 8 payments
A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $58,333 9 payments
An Open-label, Long Term Extension Study of MT-8554 in Postmenopausal Women Experiencing Moderate to Severe Vasomotor Symptoms Who Completed Study MT-8554-A01 $28,380 2 payments
M14-702 $24,732 25 payments
A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women $15,110 1 payment
1Vit15042 $13,921 6 payments
Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $8,712 1 payment
Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $7,590 6 payments
1Vit15042 $5,245 3 payments
Spirit Extension An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $4,754 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.